A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
暂无分享,去创建一个
Victor Reuter | Hartwig Huland | Markus Graefen | Robert L Sutherland | Susan M Henshall | Eric Klein | Michael W Kattan | Ilias Cagiannos | Andreas Erbersdobler | M. Kattan | P. Scardino | J. Eastham | E. Klein | C. Morash | M. Graefen | H. Huland | P. Karakiewicz | P. Kupelian | R. Sutherland | S. Henshall | P. Stricker | J. Grygiel | I. Cagiannos | A. Erbersdobler | M. Ohori | D. Quinn | V. Reuter | F. Rabbani | Peter T Scardino | David I Quinn | John J Grygiel | Phillip D Stricker | Patrick Kupelian | Peter G Hammerer | James A Eastham | Pierre Karakiewicz | Makato Ohori | Farhang Rabbani | Claudia Gerigk | Christopher G Morash | P. Hammerer | C. Gerigk
[1] M. Kattan,et al. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? , 1997, The Journal of urology.
[2] A W Partin,et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.
[3] P. Scardino,et al. Prognostic significance of lymph nodal metastases in prostate cancer. , 1989, The Journal of urology.
[4] C. Brendler,et al. Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit. , 1980, The Journal of urology.
[5] A. Haese*,et al. Validation of a biopsy‐based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma , 2002, Cancer.
[6] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[7] T. Shankey,et al. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. , 1996, Urology.
[8] H. Levin,et al. Open pelvic lymph node dissection for prostate cancer: a reassessment. , 1995, Urology.
[9] D. Bostwick,et al. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.
[10] R. Gittes,et al. Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. , 1976, The Journal of urology.
[11] S. Al-Askari,et al. Extended pelvic lymphadenectomy for prostatic cancer. , 1979, The Journal of urology.
[12] P. Narayan,et al. Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer , 1994 .
[13] G. Williams,et al. Intraoperative and early complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. , 1990, Urology.
[14] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[15] D. Bostwick,et al. Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.
[16] J. Bishoff,et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. , 1995, Urology.
[17] A. Heidenreich,et al. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.
[18] G H Hinkle,et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide , 1998, Cancer.
[19] Stefan Conrad,et al. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. , 2002, The Journal of urology.
[20] J. Cadeddu,et al. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. , 1997, Urology.